






















Journal of the American College of Cardiology Vol. 60, No. 15, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00




Is it Time to Slacken the Reins?*
Bernhard Witzenbichler, MD
Berlin, Germany
Drug-eluting stents (DES) were introduced in interven-
tional practice more than 10 years ago and rapidly replaced
bare-metal stents (BMS) for treatment of coronary artery
disease because of their superior capability to reduce the
need for restenosis-driven repeat intervention. Soon, it
became obvious that besides optimal stenting technique,
dual antiplatelet therapy (DAPT), which means the com-
bination of aspirin and a P2Y12 platelet receptor inhibitor,
has to be established for a prolonged time after stent
implantation in order to avoid potentially catastrophic stent
thrombosis (ST). In the era of first-generation DES, it
turned out that premature discontinuation of DAPT, which
means 3 months for sirolimus-eluting stents (SES) and
6 months for paclitaxel-eluting stents (PES), is a strong
predictor of ST (1,2), and this relationship is more pronounced
in patients with acute coronary syndromes receiving DES (3).
See pages 1333 and 1340
As additional safety concerns arose from reports of an increased
risk of late and very late (1 year) ST events with first-
generation DES (4,5), an attitude towards “the longer, the
better” DAPT therapy developed. This is reflected in current
guidelines of the American societies recommending at least 12
months of DAPTwith clopidogrel after DES implantation (6)
and the European Society of Cardiology endorsing 6 to 12
months of DAPT treatment after DES implantation and 12
months for all patients after ACS, irrespective of revascular-
ization strategy (7). Meanwhile, second-generation DES with
durable polymers such as everolimus-eluting stents (EES) or
zotarolimus-eluting stents (ZES) and third-generation DES
with biodegradable polymers and abluminal coating such as
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DES because of improved stent deliverability while exhib-
iting equal or superior antiproliferative efficacy, and a
consistent lower rate of late or very late ST (8,9). A recent
network meta-analysis presented the provocative finding
that within 2 years, EES might have a lower risk of ST than
BMS (10), which, unlike common perception, might be
based on the possibility that polymeric coating could reduce
stent thrombogenicity (11). This lower rate of ST with
newer-generation DES might be attributable to better
implantation technique, improved stent platform, thinner
strut thickness, more biocompatible polymers, type and
amount of antiproliferative drug, or a combination thereof.
Of note, in most contemporary DES trials, prolonged
DAPT intake for at least 12 months was mandatory,
although the optimal duration of DAPT is still lacking
scientific ground.
DAPT invariably increases the risk of major bleedings
(12). The bleeding risk correlates with the duration of
DAPT (13), and bleeding events clearly have a negative
impact on outcomes of patients after PCI (14). This raises
2 important questions, which are momentous for patients
with a high likelihood for bleeding events, with the need for
nondeferrable or unplanned noncardiac surgery or invasive
procedures, for elderly or fragile patients, and for patients
with low drug adherence: First, are there certain conditions
allowing us to safely shorten DAPT to 12 months after
DES implantation, and second, what are the consequences
of DAPT discontinuation (temporary or permanent), in
case one of these events occurs?
In this issue of the Journal, Kim et al. (15) address the
rst question. In the RESET (REal Safety and Efficacy of
-month dual antiplatelet Therapy following Endeavor
otarolimus-eluting stent implantation) trial, 2,148 patients
ith stable angina, unstable angina, or acute myocardial
nfarction (MI) undergoing elective PCI were enrolled, with
,059 randomized to the Endeavor (Medtronic, Santa Rosa,
alifornia) zotarolimus-eluting stent (E-ZES) and 3
onths of DAPT and 1,058 patients treated with standard
2-month DAPT and other DES (Resolute [Medtronic]
otarolimus-eluting stent [R-ZES], EES, or SES). Patients
ith significant left main disease, in-stent restenotic lesions,
hronic total occlusions, or patients with acute ST-segment
levation MI (STEMI) were excluded from the trial. At 12
onths, the combined endpoint of cardiovascular death,
I, ST, target vessel revascularization (TVR), or bleeding
ccurred in 4.7% of patients in both treatment arms (p 
.001 for noninferiority). Overall, there was no significant
ifference in any of the individual components of the
rimary endpoint. Definite or probable ST occurred in 2
atients (0.2%) treated with E-ZES, both within the first
onth. Three patients (0.3%) had ST in the conventional
2 months DAPT therapy arm, all of them between 3 and
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tients with diabetes mellitus and those with acute MI.
Considering the RESET trial, is it now a safe strategy to
implant E-ZES and limit DAPT to 3 months? Caution
should be advised in interpretation of the data. First, in their
power calculations, the authors assumed a 10% incidence for
the primary endpoint at 12 months with a noninferiority
margin of 4%, where in fact the event rate was low with
4.7%. Therefore, statistically, a much larger sample size
would have been needed to prove the hypothesis. Second,
the low event rate is unexpected and might in part be
explained by the anatomic low-risk profile as defined in the
inclusion/exclusion criteria of the trial, which makes it
difficult to translate the findings to a broader all-comer
population. Third, the investigators choose the E-ZES
because of a supposedly better safety profile. The phospho-
rylcholine polymer coating of the Endeavor stent accounts
for a rapid release of zotarolimus within 2 weeks, resulting
in a reduced antiproliferative effect, reflected by early neo-
intimal growth and higher late loss, which did not translate
in clinical events in patients with a low-risk profile (16), but
became evident in a more daily-practice population (17).
The hypothesis that this E-ZES–typical feature of early
neointimal growth would be protective against late ST was
challenged by the SORT OUT III (Randomized Clinical
Comparison of the Endeavor and the Cypher Coronary
Stents in Non-selected Angina Pectoris Patients) trial,
describing a 1.1% definite ST rate for E-ZES versus 0.3%
for SES (p  0.048) at 12 months (17), though the
incidence of very late ST (12 months) was consistently
low throughout the pivotal E-ZES trials (16,18). Moreover,
the follow-up time of 12 months in the RESET trial might
not be long enough to detect potential safety differences.
Fourth, industry has already reacted and replaced the
E-ZES by its successor, the Resolute-ZES (R-ZES) with a
different slow-release polymer (BioLinx) and improved
antiproliferative activity. Therefore, in most catheterization
laboratories, the E-ZES has disappeared from the shelves
and is replaced by the R-ZES. Fifth, in the control arm, a
mixture of first-generation (SES) and second-generation
DES (EES, R-ZES) was used instead of the E-ZES,
hindering direct comparisons, and finally, 14% of the
population in the trial presented with non–STEMI, the
patient group probably having the most benefit from pro-
longed DAPT by preventing future atherothrombotic
events regardless of the stent type implanted. The OPTI-
MIZE (Optimized Duration of Clopidogrel Therapy Fol-
lowing Treatment With the Endeavor Zotarolimus-Eluting
Stent in the Real World Clinical Practice) trial
(NCT01113372), currently randomizing 3,120 patients to 3
versus 12 months of DAPT after E-ZES implantation, will
probably give us a more robust insight into the safety of this
approach, although the results cannot guide catheterization
laboratories that have already abandoned the E-ZES.
The work of Ferreira-Gonza´les et al. (19) in this issue of
the Journal engages with the topic of antiplatelet therapy piscontinuation (ATD) during the first 12 months. They
ave extended their previous work on incidence and predic-
ors of ATD (20) in the same population, to the consecutive
isk for cardiac death and MI associated with it. DAPT
onadherence can be based on disruption because of bleed-
ng events or noncompliance, on the recommendation of
hysicians (medical decision) who have felt that the patients
o longer need this therapy (usually permanent), or on a
uided and recommended interruption because of a surgical
r invasive procedure, usually temporary and not longer
han 14 days; it can be brief (5 days), temporary or
ermanent. The Spanish investigators prospectively col-
ected data on 1,622 all-comer patients undergoing implan-
ation of at least 1 DES. The major findings are as follows:
irst, DAPT interruption for any reason was not infrequent
nd occurred in 10.6% of the patients, although in only 1
atient, ATD was observed within the first 4 weeks.
econd, in the majority of the patients with ATD, the
nterruption was temporary, and third, the composite end-
oint of cardiac death or acute coronary syndrome occurred
n 5.4% of all patients, but only in a minority (8%) of those
atients was ATD at any time before the event noted. In
ultivariate analysis, ATD was not found to be predictive
or future cardiac events.
The authors have to be acknowledged for their thorough
ssessment of ATD, as most trials and registries simply
ollect data of patients being “on” or “off” DAPT, ignoring
he dynamic nature of drug intake. The extent of ATD
ithin the first year was high; however, in their analysis,
verall premature ATD seemingly did not translate into
erious consequences. This may be explained by the follow-
ng issues: First, in 65% of the cases, ADT was temporary
median: 7 days), whereas it was shown that the median
nterval from discontinuation of thienopyridine to ST was
3.5 days for the first 6 months (1,21). Second, the temporal
ssociation between ATD and consecutive events beyond 6
onths is known to be lenient (22), and twice as many
atients in this study disrupted their DAPT at 6 to 12
onths. Third, because the event rates were low, the power
f the study is limited and the confidence intervals are wide.
ourth, the authors were well advised to do simulations of
TD in those patients who died of cardiac reasons. If in
8.8% of these cases DAPT had been interrupted before
eath, the association between ATD and cardiac events
ould have been significant. As it is difficult to receive
etailed information from relatives on DAPT adherence of
he deceased person, an even higher misclassification is quite
onceivable. For these reasons, the data can only suggest
hat a brief interruption of DAPT does not have a large
mpact on ischemic risk. For more information on different
odes of nonadherence to DAPT, subsequent outcomes,
nd their relation to nonadherence, we have to await the
esults of the observational PARIS (Patterns of Non-
dherence to Dual Anti-Platelet Regimen In Stented
atients) trial (NCT00998127) following more than 5,000
atients after stent placement over 2 years.
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October 9, 2012:1349–51 Early Discontinuation of Dual Antiplatelet TherapyAre these 2 reports now suggesting that the time has
come to slacken the reins in antiplatelet therapy after DES?
With newer-generation DES, 6 months DAPT might be
sufficient, and 3 months not completely of the wall in
low-risk groups. Brief interruption of DAPT beyond 4
weeks might not be associated with a dramatic risk increase.
However, the patient- and device-related criteria safely
allowing early DAPT withdrawal or interruption still have
to be determined. Until then, we should be cautious and do
our best to avoid unplanned discontinuation of DAPT.
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